Vaccinex, Inc. Stock price
Is Vaccinex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Vaccinex, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Vaccinex, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Vaccinex, Inc. forecast:
Don't miss a Thing! We will send you all news about Vaccinex, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vaccinex, Inc. Stock News
Company Profile
Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.
| Head office | United States |
| CEO | Dr. Zauderer |
| Employees | 25 |
| Founded | 1997 |
| Website | www.vaccinex.com |


